SecBot SecBot
SECBOTREPLAY Home › Report › ABT

ABT · Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15,…

ABBOTT LABORATORIES · 8-K filed Apr 16, 2026 at 07:36 ET

At the news

BEARISHIMPACT 8/10

8-K filed Apr 16, 2026 at 07:36 ET

Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase, but missed consensus by $0.00. Revenue of $11.16B grew 7.8% YoY. The company lowered full-year 2026 adjusted EPS guidance to $5.38-$5.58 (from $5.55-$5.80) due to $0.20 dilution from the Exact Sciences acquisition. Despite strong growth in Established Pharmaceuticals and Medical Devices, the guidance reduction drives a bearish sentiment.

  • First-quarter 2026 adjusted EPS was $1.15, missing consensus of $1.15 by $0.00 but up 6% YoY
  • First-quarter 2026 revenue was $11.16B, beating consensus of $11.00B and growing 7.8% YoY
  • Full-year 2026 adjusted EPS guidance was lowered to $5.38-$5.58 from $5.55-$5.80 due to $0.20 dilution from the Exact Sciences acquisition
  • The company completed the acquisition of Exact Sciences, establishing a new oncology diagnostics business

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access